The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|July 1, 2011
- Applied Clinical Trials-07-01-2011
- Volume 20
- Issue 7
Applied Clinical Trials Digital Edition - July 2011
CRO/SPONSOR : Personalized Medicine Development - Role of CROs TRIAL DESIGN : Eye Movements Help Determine Side Effect Profiles SUBJECT RECRUITMENT : Connecting Type 2 Diabetics to Clinical Trials INFORMATION TECHNOLOGY : Cloud Computing Brings Efficiencies to Life Sciences Also in this issue : Biosimilars Development, Funding in Europe, Transforming R&D, Subject Protection in India
Advertisement
Articles in this issue
over 15 years ago
Recruiting Diabetes Subjectsover 15 years ago
Eyes Play a Focal Role in Researchover 15 years ago
Fighting for Territory and Funding in Europeover 15 years ago
Cloud Computing Efficiencyover 15 years ago
Best Practice for Clinical Monitoringover 15 years ago
Personalized Medicine Developmentover 15 years ago
Italian Regulator Prepares for Europe's Top Jobover 15 years ago
Value of Time and Moneyover 15 years ago
Transforming R&D Through Open Innovationover 15 years ago
Biosimilars Development Raises Research QuestionsAdvertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5